/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

AbbVie Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$230 0.0262(2.62%) ABBV at 04 Dec 2025 04:24 PM Drug Manufacturers - General
Lowest Today 224.83
Highest Today 230.79
Today’s Open 224.84
Prev. Close 224.37
52 Week High 243.06
52 Week Low 160.33
Day’s Range: Low 224.83 High 230.79
52-Week Range: Low 160.33 High 243.06
1 day return -
1 Week return +1.06
1 month return +6.65
3 month return +8.1
6 month return +22.89
1 year return +30.4
3 year return +40.41
5 year return +114.6
10 year return -

Institutional Holdings

Vanguard Group Inc 10.04

BlackRock Inc 8.35

State Street Corp 4.53

JPMorgan Chase & Co 3.24

Vanguard Total Stock Mkt Idx Inv 3.14

Vanguard 500 Index Investor 2.48

Morgan Stanley - Brokerage Accounts 2.36

Geode Capital Management, LLC 2.22

Charles Schwab Investment Management Inc 1.52

Capital Research Global Investors 1.43

Bank of America Corp 1.42

NORGES BANK 1.31

Fidelity 500 Index 1.27

Northern Trust Corp 1.25

SPDR® S&P 500® ETF 1.21

iShares Core S&P 500 ETF 1.20

FMR Inc 1.19

Vanguard Value Index Inv 0.89

Franklin Resources Inc 0.86

UBS Asset Mgmt Americas Inc 0.83

Schwab US Dividend Equity ETF™ 0.82

Capital Research & Mgmt Co - Division 3 0.77

Bank of New York Mellon Corp 0.71

Goldman Sachs Group Inc 0.69

The Health Care Select Sector SPDR® ETF 0.68

UBS Group AG 0.67

Legal & General Group PLC 0.65

Vanguard Institutional Index I 0.60

American Funds American Mutual A 0.58

Capital Group American Mutual Comp 0.58

Vanguard Dividend Appreciation ETF 0.54

Dimensional Fund Advisors, Inc. 0.54

State St S&P 500® Indx SL Cl III 0.53

American Funds Capital Income Bldr A 0.46

Vanguard High Dividend Yield ETF 0.39

Vanguard Institutional 500 Index Trust 0.38

Blackrock Eq Idx Fund CF 0.38

iShares Russell 1000 Growth ETF 0.38

American Funds Invmt Co of Amer A 0.38

Capital Group Investment Co of Amer Comp 0.38

Market Status

Strong Buy: 12

Buy: 4

Hold: 12

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 396548.08 M

PB Ratio 50.4573

PE Ratio 169.9773

Enterprise Value 465505.48 M

Total Assets 135161.00 M

Volume 4873263

Company Financials

Annual Revenue FY24:56334000000 56334.0M, FY23:54318000000 54318.0M, FY22:58054000000 58054.0M, FY21:56197000000 56197.0M, FY20:45804000000 45804.0M

Annual Profit FY24:39430000000 39430.0M, FY23:45538000000 45538.0M, FY22:40640000000 40640.0M, FY21:38751000000 38751.0M, FY20:30417000000 30417.0M

Annual Net worth FY24:4278000000 4278.0M, FY23:4863000000 4863.0M, FY22:11836000000 11836.0M, FY21:11542000000 11542.0M, FY20:4616000000 4616.0M

Quarterly Revenue Q3/2025:15776000000 15776.0M, Q2/2025:15423000000 15423.0M, Q1/2025:13343000000 13343.0M, Q4/2024:15102000000 15102.0M, Q3/2024:14460000000 14460.0M

Quarterly Profit Q3/2025:12386000000 12386.0M, Q2/2025:13020000000 13020.0M, Q1/2025:9341000000 9341.0M, Q4/2024:10706000000 10706.0M, Q3/2024:10248000000 10248.0M

Quarterly Net worth Q3/2025:186000000 186.0M, Q2/2025:944000000 944.0M, Q1/2025:1286000000 1286.0M, Q4/2024:-22000000 -22.0M, Q3/2024:1561000000 1561.0M

Fund house & investment objective

Company Information AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Organisation Drug Manufacturers - General

Employees 55000

Industry Drug Manufacturers - General

CEO Mr. Robert A. Michael CPA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow